schliessen

Filtern

 

Bibliotheken

Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age

Highlights ► Two doses of an HBV-ISS demonstrated superior immunogenicity to three doses of HBV-Eng measured at week 28. ► HBV-ISS had a safety profile that was similar to the currently licensed HBV-Eng although injection-site reactions were more common. ► HBV-ISS achieved higher levels of protectio... Full description

Journal Title: Vaccine 2012, Vol.30 (15), p.2556-2563
Main Author: Halperin, Scott A
Other Authors: Ward, Brian , Cooper, Curtis , Predy, Gerald , Diaz-Mitoma, Francisco , Dionne, Marc , Embree, Joanne , McGeer, Allison , Zickler, Paul , Moltz, Karl-Heinz , Martz, René , Meyer, Ingo , McNeil, Shelly , Langley, Joanne M , Martins, Eduardo , Heyward, William L , Martin, J. Tyler
Format: Electronic Article Electronic Article
Language: English
Subjects:
Age
Quelle: Alma/SFX Local Collection
Publisher: Netherlands: Elsevier Ltd
ID: ISSN: 0264-410X
Link: https://www.ncbi.nlm.nih.gov/pubmed/22326642
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_929122681
title: Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age
format: Article
creator:
  • Halperin, Scott A
  • Ward, Brian
  • Cooper, Curtis
  • Predy, Gerald
  • Diaz-Mitoma, Francisco
  • Dionne, Marc
  • Embree, Joanne
  • McGeer, Allison
  • Zickler, Paul
  • Moltz, Karl-Heinz
  • Martz, René
  • Meyer, Ingo
  • McNeil, Shelly
  • Langley, Joanne M
  • Martins, Eduardo
  • Heyward, William L
  • Martin, J. Tyler
subjects:
  • Adjuvants, Immunologic
  • Adolescent
  • Adult
  • Age
  • Allergy and Immunology
  • Analysis
  • Antibody response
  • Antigens
  • Autoimmune diseases
  • Chronic illnesses
  • Comparative analysis
  • Female
  • Hepatitis
  • Hepatitis B
  • Hepatitis B - prevention & control
  • Hepatitis B Antibodies - immunology
  • Hepatitis B surface antigen
  • Hepatitis B Surface Antigens - administration & dosage
  • Hepatitis B Surface Antigens - adverse effects
  • Hepatitis B Surface Antigens - immunology
  • Hepatitis B vaccine
  • Hepatitis B Vaccines - administration & dosage
  • Hepatitis B Vaccines - adverse effects
  • Hepatitis B Vaccines - immunology
  • Hepatitis B virus
  • Hepatitis B virus - immunology
  • Humans
  • Immune response
  • Immunogenicity
  • Immunostimulation
  • Immunostimulatory sequences
  • Infections
  • Licenses
  • Liver cancer
  • Male
  • Middle Aged
  • Oligodeoxyribonucleotides - administration & dosage
  • Oligodeoxyribonucleotides - adverse effects
  • Oligodeoxyribonucleotides - immunology
  • Oligonucleotides
  • phosphorothioate
  • Randomized trial
  • Safety and security measures
  • surface antigens
  • Teenagers
  • Vaccines
  • Virus diseases
  • Young Adult
ispartof: Vaccine, 2012, Vol.30 (15), p.2556-2563
description: Highlights ► Two doses of an HBV-ISS demonstrated superior immunogenicity to three doses of HBV-Eng measured at week 28. ► HBV-ISS had a safety profile that was similar to the currently licensed HBV-Eng although injection-site reactions were more common. ► HBV-ISS achieved higher levels of protection after the first and second doses.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0264-410X
fulltext: fulltext
issn:
  • 0264-410X
  • 1873-2518
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.5882978
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_929122681
sourceformatXML
sourcesystemPC
galeidA283354555
sourcerecordidA283354555
originalsourceidFETCH-LOGICAL-c509t-755904bd59de475f1025cde67b900267c064c1b1854f88aec1570482ab871ec3
addsrcrecordideNqFU01v1DAUDAhES-HKDWSJA1x2sZ04cYQEKhVfUiUO9NCb5XVedr049tZ2tuyN_8A_5JfwtrtQ0QNVFCV5npk3eR4XxVNGp4yy-tVyutbGWA9TThmfUjalsrlbHDLZlBMumLxXHFJeV5OK0fOD4mFKS0qpKFn7oDjgvOR1XfHDO09OwrDS0abgSehJ0j3kDdG-I3YYRh_m4K2xWMLFfBlIFxKk7Yf1a0jZznW2wWtHFrDC12wTeUfWNo6JpDH22gCKIQw8MWGiu8F6mzJE6MilzQtc3DdCrWF0Ooe4IatFSHjHkBc26AwkODsPHYTvm2hnwY_GQci2gyujeREBro1p4qwBn7DDP55200LfWNYuL_Avu9HlRJj89eOnEGQDOu4U5vCouN9rl-Dx_nlUnH14f3byaXL65ePnk-PTiRG0zZNGiJZWs060HVSN6BnlwnRQN7OW4vAbQ-vKsBmTouql1GCYaGgluZ7JhoEpj4oXO9lVDBcjzlMNNhlwTnsIY1ItbxnntWSIfPlfJKNUyoq2rEXo8xvQZRgj7hGiRNUwlJMSUdMdaq4dKOv7kKM2eHUwWBM89Bbrx1yWpaiEEEgQO4KJIaUIvVpFO-i4wd5qG0m1VPshq20kFWUKI4m8Z3s742yA7i_rTwYR8PqGMAbuKlboyLpb5d_u2IDbtLYQVTIWvIHORjBZdcHeqvDmhoJxmFKj3TfYQLoenkrIUV-3p2p7qBinlFXyvPwNE9wk1g
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1547168188
display
typearticle
titleComparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age
sourceAlma/SFX Local Collection
creatorHalperin, Scott A ; Ward, Brian ; Cooper, Curtis ; Predy, Gerald ; Diaz-Mitoma, Francisco ; Dionne, Marc ; Embree, Joanne ; McGeer, Allison ; Zickler, Paul ; Moltz, Karl-Heinz ; Martz, René ; Meyer, Ingo ; McNeil, Shelly ; Langley, Joanne M ; Martins, Eduardo ; Heyward, William L ; Martin, J. Tyler
creatorcontribHalperin, Scott A ; Ward, Brian ; Cooper, Curtis ; Predy, Gerald ; Diaz-Mitoma, Francisco ; Dionne, Marc ; Embree, Joanne ; McGeer, Allison ; Zickler, Paul ; Moltz, Karl-Heinz ; Martz, René ; Meyer, Ingo ; McNeil, Shelly ; Langley, Joanne M ; Martins, Eduardo ; Heyward, William L ; Martin, J. Tyler
descriptionHighlights ► Two doses of an HBV-ISS demonstrated superior immunogenicity to three doses of HBV-Eng measured at week 28. ► HBV-ISS had a safety profile that was similar to the currently licensed HBV-Eng although injection-site reactions were more common. ► HBV-ISS achieved higher levels of protection after the first and second doses.
identifier
0ISSN: 0264-410X
1EISSN: 1873-2518
2DOI: 10.1016/j.vaccine.2012.01.087
3PMID: 22326642
languageeng
publisherNetherlands: Elsevier Ltd
subjectAdjuvants, Immunologic ; Adolescent ; Adult ; Age ; Allergy and Immunology ; Analysis ; Antibody response ; Antigens ; Autoimmune diseases ; Chronic illnesses ; Comparative analysis ; Female ; Hepatitis ; Hepatitis B ; Hepatitis B - prevention & control ; Hepatitis B Antibodies - immunology ; Hepatitis B surface antigen ; Hepatitis B Surface Antigens - administration & dosage ; Hepatitis B Surface Antigens - adverse effects ; Hepatitis B Surface Antigens - immunology ; Hepatitis B vaccine ; Hepatitis B Vaccines - administration & dosage ; Hepatitis B Vaccines - adverse effects ; Hepatitis B Vaccines - immunology ; Hepatitis B virus ; Hepatitis B virus - immunology ; Humans ; Immune response ; Immunogenicity ; Immunostimulation ; Immunostimulatory sequences ; Infections ; Licenses ; Liver cancer ; Male ; Middle Aged ; Oligodeoxyribonucleotides - administration & dosage ; Oligodeoxyribonucleotides - adverse effects ; Oligodeoxyribonucleotides - immunology ; Oligonucleotides ; phosphorothioate ; Randomized trial ; Safety and security measures ; surface antigens ; Teenagers ; Vaccines ; Virus diseases ; Young Adult
ispartofVaccine, 2012, Vol.30 (15), p.2556-2563
rights
0Elsevier Ltd
12012 Elsevier Ltd
2Copyright © 2012 Elsevier Ltd. All rights reserved.
3COPYRIGHT 2012 Elsevier B.V.
4Copyright Elsevier Limited Mar 28, 2012
lds50peer_reviewed
citedbyFETCH-LOGICAL-c509t-755904bd59de475f1025cde67b900267c064c1b1854f88aec1570482ab871ec3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22326642$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Halperin, Scott A
1Ward, Brian
2Cooper, Curtis
3Predy, Gerald
4Diaz-Mitoma, Francisco
5Dionne, Marc
6Embree, Joanne
7McGeer, Allison
8Zickler, Paul
9Moltz, Karl-Heinz
10Martz, René
11Meyer, Ingo
12McNeil, Shelly
13Langley, Joanne M
14Martins, Eduardo
15Heyward, William L
16Martin, J. Tyler
title
0Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age
1Vaccine
addtitleVaccine
descriptionHighlights ► Two doses of an HBV-ISS demonstrated superior immunogenicity to three doses of HBV-Eng measured at week 28. ► HBV-ISS had a safety profile that was similar to the currently licensed HBV-Eng although injection-site reactions were more common. ► HBV-ISS achieved higher levels of protection after the first and second doses.
subject
0Adjuvants, Immunologic
1Adolescent
2Adult
3Age
4Allergy and Immunology
5Analysis
6Antibody response
7Antigens
8Autoimmune diseases
9Chronic illnesses
10Comparative analysis
11Female
12Hepatitis
13Hepatitis B
14Hepatitis B - prevention & control
15Hepatitis B Antibodies - immunology
16Hepatitis B surface antigen
17Hepatitis B Surface Antigens - administration & dosage
18Hepatitis B Surface Antigens - adverse effects
19Hepatitis B Surface Antigens - immunology
20Hepatitis B vaccine
21Hepatitis B Vaccines - administration & dosage
22Hepatitis B Vaccines - adverse effects
23Hepatitis B Vaccines - immunology
24Hepatitis B virus
25Hepatitis B virus - immunology
26Humans
27Immune response
28Immunogenicity
29Immunostimulation
30Immunostimulatory sequences
31Infections
32Licenses
33Liver cancer
34Male
35Middle Aged
36Oligodeoxyribonucleotides - administration & dosage
37Oligodeoxyribonucleotides - adverse effects
38Oligodeoxyribonucleotides - immunology
39Oligonucleotides
40phosphorothioate
41Randomized trial
42Safety and security measures
43surface antigens
44Teenagers
45Vaccines
46Virus diseases
47Young Adult
issn
00264-410X
11873-2518
fulltexttrue
rsrctypearticle
creationdate2012
recordtypearticle
recordideNqFU01v1DAUDAhES-HKDWSJA1x2sZ04cYQEKhVfUiUO9NCb5XVedr049tZ2tuyN_8A_5JfwtrtQ0QNVFCV5npk3eR4XxVNGp4yy-tVyutbGWA9TThmfUjalsrlbHDLZlBMumLxXHFJeV5OK0fOD4mFKS0qpKFn7oDjgvOR1XfHDO09OwrDS0abgSehJ0j3kDdG-I3YYRh_m4K2xWMLFfBlIFxKk7Yf1a0jZznW2wWtHFrDC12wTeUfWNo6JpDH22gCKIQw8MWGiu8F6mzJE6MilzQtc3DdCrWF0Ooe4IatFSHjHkBc26AwkODsPHYTvm2hnwY_GQci2gyujeREBro1p4qwBn7DDP55200LfWNYuL_Avu9HlRJj89eOnEGQDOu4U5vCouN9rl-Dx_nlUnH14f3byaXL65ePnk-PTiRG0zZNGiJZWs060HVSN6BnlwnRQN7OW4vAbQ-vKsBmTouql1GCYaGgluZ7JhoEpj4oXO9lVDBcjzlMNNhlwTnsIY1ItbxnntWSIfPlfJKNUyoq2rEXo8xvQZRgj7hGiRNUwlJMSUdMdaq4dKOv7kKM2eHUwWBM89Bbrx1yWpaiEEEgQO4KJIaUIvVpFO-i4wd5qG0m1VPshq20kFWUKI4m8Z3s742yA7i_rTwYR8PqGMAbuKlboyLpb5d_u2IDbtLYQVTIWvIHORjBZdcHeqvDmhoJxmFKj3TfYQLoenkrIUV-3p2p7qBinlFXyvPwNE9wk1g
startdate2012
enddate2012
creator
0Halperin, Scott A
1Ward, Brian
2Cooper, Curtis
3Predy, Gerald
4Diaz-Mitoma, Francisco
5Dionne, Marc
6Embree, Joanne
7McGeer, Allison
8Zickler, Paul
9Moltz, Karl-Heinz
10Martz, René
11Meyer, Ingo
12McNeil, Shelly
13Langley, Joanne M
14Martins, Eduardo
15Heyward, William L
16Martin, J. Tyler
general
0Elsevier Ltd
1Elsevier B.V
2Elsevier Limited
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
93V.
107QL
117RV
127T2
137T5
147U9
157X7
167XB
1788C
1888E
198AO
208C1
218FE
228FH
238FI
248FJ
258FK
268G5
27ABUWG
28AZQEC
29BBNVY
30BENPR
31BHPHI
32C1K
33DWQXO
34FYUFA
35GHDGH
36GNUQQ
37GUQSH
38H94
39HCIFZ
40K9-
41K9.
42KB0
43LK8
44M0R
45M0S
46M0T
47M1P
48M2O
49M7N
50M7P
51MBDVC
52NAPCQ
53PQEST
54PQQKQ
55PQUKI
56Q9U
577X8
sort
creationdate2012
titleComparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age
authorHalperin, Scott A ; Ward, Brian ; Cooper, Curtis ; Predy, Gerald ; Diaz-Mitoma, Francisco ; Dionne, Marc ; Embree, Joanne ; McGeer, Allison ; Zickler, Paul ; Moltz, Karl-Heinz ; Martz, René ; Meyer, Ingo ; McNeil, Shelly ; Langley, Joanne M ; Martins, Eduardo ; Heyward, William L ; Martin, J. Tyler
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c509t-755904bd59de475f1025cde67b900267c064c1b1854f88aec1570482ab871ec3
rsrctypearticles
prefilterarticles
languageeng
creationdate2012
topic
0Adjuvants, Immunologic
1Adolescent
2Adult
3Age
4Allergy and Immunology
5Analysis
6Antibody response
7Antigens
8Autoimmune diseases
9Chronic illnesses
10Comparative analysis
11Female
12Hepatitis
13Hepatitis B
14Hepatitis B - prevention & control
15Hepatitis B Antibodies - immunology
16Hepatitis B surface antigen
17Hepatitis B Surface Antigens - administration & dosage
18Hepatitis B Surface Antigens - adverse effects
19Hepatitis B Surface Antigens - immunology
20Hepatitis B vaccine
21Hepatitis B Vaccines - administration & dosage
22Hepatitis B Vaccines - adverse effects
23Hepatitis B Vaccines - immunology
24Hepatitis B virus
25Hepatitis B virus - immunology
26Humans
27Immune response
28Immunogenicity
29Immunostimulation
30Immunostimulatory sequences
31Infections
32Licenses
33Liver cancer
34Male
35Middle Aged
36Oligodeoxyribonucleotides - administration & dosage
37Oligodeoxyribonucleotides - adverse effects
38Oligodeoxyribonucleotides - immunology
39Oligonucleotides
40phosphorothioate
41Randomized trial
42Safety and security measures
43surface antigens
44Teenagers
45Vaccines
46Virus diseases
47Young Adult
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Halperin, Scott A
1Ward, Brian
2Cooper, Curtis
3Predy, Gerald
4Diaz-Mitoma, Francisco
5Dionne, Marc
6Embree, Joanne
7McGeer, Allison
8Zickler, Paul
9Moltz, Karl-Heinz
10Martz, René
11Meyer, Ingo
12McNeil, Shelly
13Langley, Joanne M
14Martins, Eduardo
15Heyward, William L
16Martin, J. Tyler
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8ProQuest Central (Corporate)
9Bacteriology Abstracts (Microbiology B)
10Nursing & Allied Health Database
11Health and Safety Science Abstracts (Full archive)
12Immunology Abstracts
13Virology and AIDS Abstracts
14Health & Medical Collection
15ProQuest Central (purchase pre-March 2016)
16Healthcare Administration Database (Alumni)
17Medical Database (Alumni Edition)
18ProQuest Pharma Collection
19Public Health Database
20ProQuest SciTech Collection
21ProQuest Natural Science Collection
22Hospital Premium Collection
23Hospital Premium Collection (Alumni Edition)
24ProQuest Central (Alumni) (purchase pre-March 2016)
25Research Library (Alumni Edition)
26ProQuest Central (Alumni Edition)
27ProQuest Central Essentials
28Biological Science Collection
29ProQuest Central
30Natural Science Collection
31Environmental Sciences and Pollution Management
32ProQuest Central Korea
33Health Research Premium Collection
34Health Research Premium Collection (Alumni)
35ProQuest Central Student
36Research Library Prep
37AIDS and Cancer Research Abstracts
38SciTech Premium Collection
39Consumer Health Database (Alumni Edition)
40ProQuest Health & Medical Complete (Alumni)
41Nursing & Allied Health Database (Alumni Edition)
42ProQuest Biological Science Collection
43Consumer Health Database
44Health & Medical Collection (Alumni Edition)
45Healthcare Administration Database
46Medical Database
47Research Library
48Algology Mycology and Protozoology Abstracts (Microbiology C)
49Biological Science Database
50Research Library (Corporate)
51Nursing & Allied Health Premium
52ProQuest One Academic Eastern Edition
53ProQuest One Academic
54ProQuest One Academic UKI Edition
55ProQuest Central Basic
56MEDLINE - Academic
jtitleVaccine
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Halperin, Scott A
1Ward, Brian
2Cooper, Curtis
3Predy, Gerald
4Diaz-Mitoma, Francisco
5Dionne, Marc
6Embree, Joanne
7McGeer, Allison
8Zickler, Paul
9Moltz, Karl-Heinz
10Martz, René
11Meyer, Ingo
12McNeil, Shelly
13Langley, Joanne M
14Martins, Eduardo
15Heyward, William L
16Martin, J. Tyler
formatjournal
genrearticle
ristypeJOUR
atitleComparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age
jtitleVaccine
addtitleVaccine
date2012
risdate2012
volume30
issue15
spage2556
epage2563
pages2556-2563
issn0264-410X
eissn1873-2518
abstractHighlights ► Two doses of an HBV-ISS demonstrated superior immunogenicity to three doses of HBV-Eng measured at week 28. ► HBV-ISS had a safety profile that was similar to the currently licensed HBV-Eng although injection-site reactions were more common. ► HBV-ISS achieved higher levels of protection after the first and second doses.
copNetherlands
pubElsevier Ltd
pmid22326642
doi10.1016/j.vaccine.2012.01.087